We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is Thermo Fisher (TMO) Down 3.9% Since Last Earnings Report?
Read MoreHide Full Article
A month has gone by since the last earnings report for Thermo Fisher Scientific (TMO - Free Report) . Shares have lost about 3.9% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Thermo Fisher due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Thermo Fisher Q2 Earnings Miss Estimates, Margins Down
Thermo Fisher Scientific’s second-quarter 2023 adjusted earnings per share of $5.15 lagged the Zacks Consensus Estimate by 5.2%. The figure also declined 6.5% year over year.
The adjusted number excludes certain non-recurring expenses, including asset amortization costs and certain restructuring costs.
GAAP EPS was $3.51, down 18.8% on a year-over-year basis.
Revenues in Detail
Revenues in the quarter totaled $10.69 billion, down 2.6% year over year. The top line lagged the Zacks Consensus Estimate by 2.8%.
Segment Details
Organic revenues in the reported quarter declined 3% year over year, while Core organic revenue growth was 2%.
Thermo Fisher operates under four business segments — Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics and Laboratory Products and Biopharma Services.
Revenues in the Life Sciences Solutions segment (23% of total revenues) declined 25.2% year over year to $2.46 billion, while Analytical Instruments Segment sales (16.4%) increased 8.8% to $1.75 billion.
Revenues in the Laboratory Products and Biopharma Services segment (54.6%) rose 5.3% to $5.83 billion. The Specialty Diagnostics segment (10.4%) recorded a 0.7% year-over-year rise in revenues to $1.11 billion.
Margin Analysis
The gross margin of 40.8% in the second quarter contracted 228 basis points (bps) year over year on a 1.3% rise in the cost of revenues.
In the quarter, selling, general and administrative expenses fell 3.9% to $1.67 billion. Research and development expenses declined 5.5% to $345 million.
The adjusted operating margin in the quarter came in at 21.9%, reflecting a contraction of 198 bps.
Financial Position
The company exited second-quarter 2023 with cash and cash equivalents of $3.13 billion compared with $3.48 billion at the end of first-quarter 2023.
Cumulative net cash provided by operating activities was $2.27 billion compared with $3.73 billion a year ago.
Thermo Fisher has a consistent dividend-paying history, with the five-year annualized dividend growth being 16.43%.
Guidance
Thermo Fisher updated its full-year 2023 guidance.
The company expects 2023 revenues in the range of $43.4-$44.0 billion, with Core organic revenue growth of 2-4%. The Zacks Consensus Estimate for the same is pegged at $45.24 billion.
The adjusted EPS is expected in the range of $22.28-$22.72. The Zacks Consensus Estimate for the metric is pegged at $23.60 billion.
How Have Estimates Been Moving Since Then?
It turns out, estimates review have trended downward during the past month.
The consensus estimate has shifted -11.9% due to these changes.
VGM Scores
At this time, Thermo Fisher has a subpar Growth Score of D, though it is lagging a bit on the Momentum Score front with an F. However, the stock was allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise Thermo Fisher has a Zacks Rank #4 (Sell). We expect a below average return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Is Thermo Fisher (TMO) Down 3.9% Since Last Earnings Report?
A month has gone by since the last earnings report for Thermo Fisher Scientific (TMO - Free Report) . Shares have lost about 3.9% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Thermo Fisher due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Thermo Fisher Q2 Earnings Miss Estimates, Margins Down
Thermo Fisher Scientific’s second-quarter 2023 adjusted earnings per share of $5.15 lagged the Zacks Consensus Estimate by 5.2%. The figure also declined 6.5% year over year.
The adjusted number excludes certain non-recurring expenses, including asset amortization costs and certain restructuring costs.
GAAP EPS was $3.51, down 18.8% on a year-over-year basis.
Revenues in Detail
Revenues in the quarter totaled $10.69 billion, down 2.6% year over year. The top line lagged the Zacks Consensus Estimate by 2.8%.
Segment Details
Organic revenues in the reported quarter declined 3% year over year, while Core organic revenue growth was 2%.
Thermo Fisher operates under four business segments — Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics and Laboratory Products and Biopharma Services.
Revenues in the Life Sciences Solutions segment (23% of total revenues) declined 25.2% year over year to $2.46 billion, while Analytical Instruments Segment sales (16.4%) increased 8.8% to $1.75 billion.
Revenues in the Laboratory Products and Biopharma Services segment (54.6%) rose 5.3% to $5.83 billion. The Specialty Diagnostics segment (10.4%) recorded a 0.7% year-over-year rise in revenues to $1.11 billion.
Margin Analysis
The gross margin of 40.8% in the second quarter contracted 228 basis points (bps) year over year on a 1.3% rise in the cost of revenues.
In the quarter, selling, general and administrative expenses fell 3.9% to $1.67 billion. Research and development expenses declined 5.5% to $345 million.
The adjusted operating margin in the quarter came in at 21.9%, reflecting a contraction of 198 bps.
Financial Position
The company exited second-quarter 2023 with cash and cash equivalents of $3.13 billion compared with $3.48 billion at the end of first-quarter 2023.
Cumulative net cash provided by operating activities was $2.27 billion compared with $3.73 billion a year ago.
Thermo Fisher has a consistent dividend-paying history, with the five-year annualized dividend growth being 16.43%.
Guidance
Thermo Fisher updated its full-year 2023 guidance.
The company expects 2023 revenues in the range of $43.4-$44.0 billion, with Core organic revenue growth of 2-4%. The Zacks Consensus Estimate for the same is pegged at $45.24 billion.
The adjusted EPS is expected in the range of $22.28-$22.72. The Zacks Consensus Estimate for the metric is pegged at $23.60 billion.
How Have Estimates Been Moving Since Then?
It turns out, estimates review have trended downward during the past month.
The consensus estimate has shifted -11.9% due to these changes.
VGM Scores
At this time, Thermo Fisher has a subpar Growth Score of D, though it is lagging a bit on the Momentum Score front with an F. However, the stock was allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise Thermo Fisher has a Zacks Rank #4 (Sell). We expect a below average return from the stock in the next few months.